Cloud Network Management: How Dentists Can Reduce Downtime With 24/7 Monitoring

Fort Wayne, Indiana / / January 5, 2026 / Aptica, LLC Modern dental practices depend heavily on technology to deliver quality ...

Idorsia Pharmaceuticals Ltd: Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

The trial aims to establish clinical proof-of-concept in psoriasis and proof-of-mechanism for other CCR6- and Th17-associated autoimmune indications Allschwil, Switzerland - January 6, 2026Idorsia ...

Drones are saving snakebite victims in Ghana – but only when the mobile signal works

A US logistics company has completed 8 million deliveries across six distribution centres, but mobile connectivity gaps are ...
Kauppalehti

Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

Psoriasis is a chronic, immune-mediated skin condition driven by the IL-23/Th17 pathway, characterized by elevated CCL20 and CCR6-positive cells in affected skin.1 There is a significant need for oral ...